Public Employees Retirement System of Ohio Makes New $43.42 Million Investment in Medtronic PLC $MDT

Posted by Brenda Bartman on Aug 28th, 2026

Public Employees Retirement System of Ohio acquired a new position in Medtronic PLC (NYSE:MDT – Free Report) in the 2nd quarter, Holdings Channel reports. The institutional investor acquired 555,013 shares of the medical technology company’s stock, valued at approximately $43,419,000.

Several other large investors have also recently bought and sold shares of MDT. Madison Asset Management LLC raised its holdings in shares of Medtronic by 15.0% during the 4th quarter. Madison Asset Management LLC now owns 195,216 shares of the medical technology company’s stock worth $18,752,000 after buying an additional 25,527 shares in the last quarter. First Eagle Investment Management LLC grew its position in Medtronic by 0.4% in the fourth quarter. First Eagle Investment Management LLC now owns 9,775,234 shares of the medical technology company’s stock valued at $939,009,000 after acquiring an additional 40,196 shares during the last quarter. Gradient Investments LLC raised its stake in Medtronic by 3.9% during the second quarter. Gradient Investments LLC now owns 496,513 shares of the medical technology company’s stock worth $38,842,000 after acquiring an additional 18,509 shares in the last quarter. Czech National Bank raised its stake in Medtronic by 4.7% during the second quarter. Czech National Bank now owns 365,443 shares of the medical technology company’s stock worth $28,589,000 after acquiring an additional 16,292 shares in the last quarter. Finally, Cerity Partners LLC lifted its holdings in shares of Medtronic by 12.7% in the fourth quarter. Cerity Partners LLC now owns 791,015 shares of the medical technology company’s stock worth $75,988,000 after acquiring an additional 89,111 shares during the last quarter. Institutional investors and hedge funds own 82.06% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on MDT shares. Wells Fargo & Company decreased their price target on shares of Medtronic from $114.00 to $102.00 and set an “overweight” rating on the stock in a report on Thursday, June 4th. Truist Financial cut their target price on shares of Medtronic from $95.00 to $86.00 and set a “hold” rating on the stock in a research report on Thursday, June 4th. Evercore set a $105.00 target price on shares of Medtronic in a research note on Monday, July 6th. Rothschild & Co Redburn dropped their price target on Medtronic from $111.00 to $106.00 and set a “buy” rating for the company in a research note on Friday, June 5th. Finally, Royal Bank Of Canada restated an “outperform” rating and set a $118.00 price objective on shares of Medtronic in a research report on Thursday, June 4th. Eighteen analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat.com, Medtronic has a consensus rating of “Moderate Buy” and an average price target of $99.38.

Read Our Latest Stock Report on MDT

Medtronic Stock Performance

NYSE MDT opened at $90.04 on Friday. The company has a market capitalization of $115.24 billion, a price-to-earnings ratio of 24.14, a PEG ratio of 2.47 and a beta of 0.55. Medtronic PLC has a twelve month low of $73.31 and a twelve month high of $106.33. The stock has a fifty day simple moving average of $85.34 and a 200 day simple moving average of $85.63. The company has a quick ratio of 1.62, a current ratio of 2.13 and a debt-to-equity ratio of 0.52.

Medtronic (NYSE:MDT – Get Free Report) last posted its quarterly earnings data on Wednesday, June 3rd. The medical technology company reported $1.55 earnings per share for the quarter, topping the consensus estimate of $1.54 by $0.01. The company had revenue of $9.81 billion during the quarter, compared to analysts’ expectations of $9.62 billion. Medtronic had a net margin of 13.20% and a return on equity of 14.51%. Medtronic’s revenue for the quarter was up 9.9% compared to the same quarter last year. During the same period in the prior year, the company posted $1.62 earnings per share. Medtronic has set its FY 2027 guidance at 5.900-6.000 EPS. Sell-side analysts expect that Medtronic PLC will post 5.94 EPS for the current year.

Medtronic Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, October 16th. Shareholders of record on Friday, September 25th will be paid a dividend of $0.72 per share. The ex-dividend date is Friday, September 25th. This represents a $2.88 dividend on an annualized basis and a yield of 3.2%. Medtronic’s payout ratio is 77.21%.

Key Headlines Impacting Medtronic

Here are the key news stories impacting Medtronic this week:

Positive Sentiment: Needham raised its price target to $114 from $101 and reiterated a Buy rating, implying substantial upside from recent trading levels. The firm expects Medtronic to beat first-quarter estimates and raise its fiscal 2027 guidance, potentially providing a near-term catalyst. Medtronic price target raised by Needham
Positive Sentiment: Analysts expect continued growth across Medtronic’s Cardiovascular, Neuroscience and Diabetes businesses. Cardiovascular performance and expanding renal-denervation activity are highlighted as important growth opportunities. Medtronic Q1 estimates and guidance
Positive Sentiment: Medtronic reaffirmed its dividend trajectory, approving a $0.72-per-share fiscal 2027 second-quarter dividend. The ongoing dividend supports the stock’s appeal to income-oriented investors. Medtronic dividend update
Positive Sentiment: Recent coverage points to strengthening device momentum and a potential rebound, while Medtronic remains viewed as a relatively inexpensive, diversified alternative to faster-growing surgical-robotics companies. Medtronic device momentum

Insider Buying and Selling

In other Medtronic news, EVP Harry Skip Kiil sold 4,189 shares of the firm’s stock in a transaction on Monday, June 8th. The stock was sold at an average price of $80.44, for a total transaction of $336,963.16. Following the transaction, the executive vice president directly owned 37,227 shares in the company, valued at approximately $2,994,539.88. This trade represents a 10.11% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.27% of the company’s stock.

Medtronic Profile

(Free Report)

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).